Price (delayed)
$284.88
Market cap
$5.21B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18.1
Enterprise value
$5.18B
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum
There are no recent dividends present for MDGL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.